Abstract
Introduction:
Fluorescence Lifetime Imaging Microscopy (FLIM) is an imaging technique that allows for the visualization of the cellular microenvironment by measuring the decay time of endogenous fluorescent molecules. Its advent has allowed the acquisition of information on previously undetectable aspects of the tissue environment, which also includes some mechanisms involving immune checkpoints. Understanding the level of interaction with their ligands is of paramount importance when stratifying patients for immunotherapy, as traditional methods such as immunohistochemistry (IHC) were found to be ineffective in predicting responders.
Methods:
This review analyzes the current literature on FLIM as a means of predicting targets’ responsiveness to ICIs by examining the most relevant databases. Following PRISMA guidelines, we identified the relevant literature. The predefined objective of this review was to evaluate the potential of FLIM as a predictive biomarker of responsiveness to immune checkpoint inhibitors (ICIs). Eligibility criteria included original studies (clinical or preclinical) reporting on the use of FLIM to assess tumor or immune microenvironment in the context of ICI therapy. Reviews, case reports, editorials, and abstracts without full text were excluded.
Results:
Research suggests that interaction, not expression, is positively correlated with the effectiveness of ICI treatment. FLIM, in combination with FRET, allows for the quantification of the interactions within the tumor microenvironment.
Discussion:
The scope of the review is to assist researchers in further exploring this technology for possible applications and for future drug interaction studies.
1 Introduction
The advent of Immune Checkpoint Inhibitors (ICI) revolutionized oncological therapies by enabling the immune system to fight against cancer. Despite their effectiveness on many tumors, only 20-40% () of patients are estimated to respond to immunotherapy. One of the main issues is represented by non-responders. Given the high cost of treatment and potential side effects, developing reliable methods for predicting patients’ response to these drugs is paramount.
1.1 The issue
The predictive value of ICI response is traditionally based on the evaluation of immunohistochemical (IHC) expression of specific proteins (i.e., PD-L1) detectable in patients’ neoplastic tissue, mostly in the advanced stages of the disease. The PD-1/PD-L1 and CTLA-4 axes are described in detail in the Supplementary Material. In the last 15 years, advanced automated techniques have been developed for the preparation of stained sections with monoclonal antibodies to minimize interpretation errors and standardize immunohistochemical analysis. However, this method is not without limitations, leading to very low predictive value and poor patient stratification. It has been demonstrated that some patients with high PD-L1 expression do not respond to ICIs. In contrast, others with low or absent PD-L1 expression may still derive benefit, highlighting the imperfect nature of this biomarker ().
In the pursuit of more accurate and reliable methods for visualizing molecular interactions, researchers have turned to advanced imaging techniques like Fluorescence Lifetime Imaging Microscopy (FLIM) and Förster Resonance Energy Transfer (FRET). FLIM, which emerged in the late 1980s, initially focused on measuring the decay rates of fluorescent molecules, offering a novel way to study the microenvironment of these molecules beyond what was possible with traditional fluorescence intensity imaging. Over the decades, continuous technological advancements and refinements have expanded FLIM’s applications, making it a crucial tool for real-time visualization of molecular dynamics. Today, FLIM, often coupled with FRET, allows for the detailed examination of the molecular environment and interactions through autofluorescence of cellular components (e.g., NADH, collagen) or fluorescent probes labeling target molecules. These technologies provide high spatial and temporal resolution (), enabling researchers to gain deep insights into cellular processes and molecular interactions, thus paving the way for breakthroughs in fields like cancer research and immunotherapy.
Current research has focused primarily on PD-1 and its ligand PD-L1, but new research is emerging on CTLA-4. With proper standardization of protocols, this technology may represent a reliable and effective tool for the analysis of sensitivity in candidate patients to ICI treatment.
1.2 FLIM and FRET measurement
FLIM and FRET are powerful biomedical imaging and molecular biology techniques. FLIM measures the fluorescence decay rate from excited molecules (Figures 1, 2), providing information on the local biochemical environment. On the other hand, FRET detects energy transfer between two fluorophores in close proximity, allowing for the study of molecular interactions and dynamics.
Figure 1
Figure 2
FLIM-FRET techniques, more thoroughly explained in the Supplementary Material, measure the fluorescence lifetime of the donor, avoiding contamination from the acceptor. FRET efficiency is determined by comparing the donor’s fluorescence lifetimes in the presence and absence of FRET. This method allows clear visualization of lifetime decreases in regions where FRET occurs (, ). The main advantages of FLIM-based FRET measurements include the ability to distinguish between interacting and non-interacting donor fractions, which is crucial for protein-interaction experiments that often involve a mix of interacting and non-interacting proteins (, ).
1.3 Research scope and questions
This review will provide a comprehensive analysis of the current state of FLIM technology for the qualitative and quantitative evaluation of ICI response. We will highlight the advantages and limitations of this relatively new technology based on the most relevant studies in the recent literature. Lastly, we will address current challenges and future directions for this technology. The questions that guided this review were: Is FLIM equally as effective at quantifying immune receptor expression as IHC? Can FLIM be used to stratify patients for ICI treatment better than IHC? What are its strengths and limitations?
2 Materials and methods
2.1 Selection criteria
After formulating the research question and reviewing PRISMA methodologies for systematic reviews, the team agreed on a comprehensive literature identification, screening, and documentation approach. Our research included literature focusing on predicting ICI response through FLIM written in either English or Italian. Eligible studies included retrospective cohort studies, case series, in vitro experiments, in vivo animal models, and other non-randomized observational studies. Exclusion criteria included conference abstracts, reviews, case studies, and studies lacking relevant conclusions.
2.2 Search strategy, data extraction, and analysis
The PRISMA checklist for systematic reviews was used to draft our work and ensure quality. The search was conducted on April 15, 2025, spanning several sources selected for their relevance to immunology, immunotherapy, and fluorescence imaging. Specifically, the search was performed on PubMed, Embase, and Scopus. Both reference-list scanning and grey literature research were undertaken. Everything is summarized in the flowchart (Figure 3).
Figure 3
The following keywords and MeSH were used: “((FLIM) OR (FRET) OR (fluorescence lifetime)) AND ((PD-1) OR (PD-L1) OR (programmed death ligand 1) OR (CTLA4) OR (LAG-3) OR (TIM-3))” on PubMed, “(flim OR fret OR ‘fluorescence lifetime’) AND (‘pd 1’ OR ‘pd l1’ OR ‘programmed death ligand 1’ OR ctla4 OR ‘lag 3’ OR ‘tim 3’)” on Embase, and “(TITLE-ABS-KEY (flim) OR TITLE-ABS-KEY (fret) OR TITLE-ABS-KEY (“fluorescence lifetime”) AND TITLE-ABS-KEY (pd-1) OR TITLE-ABS-KEY (pd-l1) OR TITLE-ABS-KEY (“programmed death ligand 1”) OR TITLE-ABS-KEY (ctla-4) OR TITLE-ABS-KEY (lag-3) OR TITLE-ABS-KEY (tim-3))” on Scopus. The search yielded relevant articles published in “Analytica” by MDPI, “Research Square”, “CTM”, “Cancer Research” by AACR, “Journal of Surgical Oncology” by Wiley, and “Biophysical Chemistry”. Furthermore, reference scanning was performed on these articles. The first- and second-level screening, and data extraction were performed independently by several authors (CC, GF, ML, GM, AM, and FP) to ensure robustness and minimize errors.
2.3 Risk of bias assessment
Across the included studies, the overall risk of bias was moderate, Table 1. None of the studies were RCTs, and the two human studies (, ) were retrospective cohorts with inherent confounding and selection biases. These observational studies did not properly control for all potential prognostic factors, which could significantly influence the observed association between FLIM-based biomarkers and ICI outcomes. However, objective endpoints have been applied (e.g., survival) and, in one case, a blinded multi-site assay analysis to mitigate measurement bias (Sánchez-Magraner et al., 2023). The in vitro proof-of-concept study was at low risk of bias, benefiting from a controlled experimental setup and objective readouts. The preclinical animal studies were generally well-conducted but still exhibited some risk of bias common to exploratory animal experiments, such as unclear blinding of outcome assessment and, in one case, non-random group assignment. One murine study did implement randomization for therapy vs. control groups, strengthening its internal validity. Overall, while all included studies had methodological limitations (e.g., retrospective design, small sample sizes, or incomplete reporting of blinding), no study was found to have a high or critical risk of bias. This suggests that the current evidence, though preliminary, is not compromised by fatal bias; still, the moderate risk-of-bias across studies underscores the need for cautious interpretation of the findings and highlights the importance of more rigorous future research (e.g., prospective trials) to confirm FLIM’s predictive value.
Table 1
| Reference | Study type | Risk of bias tool | Bias domains assessed | Overall risk of bias |
|---|---|---|---|---|
| () | Retrospective human biomarker study (multicenter observational) | ROBINS-I (non-randomized studies) | Confounding (no randomization), selection bias (retrospective cohort), outcome measurement (blinding not reported), missing data, selective reporting | Moderate – Retrospective design and single-region sampling may introduce selection bias and confounding, though outcomes (survival) were objective. |
| () | Experimental in vitro study (cell membrane assay) | No standard tool (custom domains) | Sample selection and reproducibility, performance consistency (controls with/without drug), detection bias (instrument measurement), reporting transparency | Low – Well-controlled proof-of-concept experiment with appropriate controls (± pembrolizumab) and objective measurements, yielding minimal risk of bias. |
| () | Retrospective human biomarker study (NSCLC patients) | ROBINS-I (non-randomized studies) | Confounding (retrospective with varying patient factors), selection bias (multisite sample selection), performance bias (not applicable – single-arm), detection bias (blinded PD-1/PD-L1 assay), missing data, selective reporting | Moderate – No randomization and potential confounders (e.g., heterogeneity in clinical data) limit causal inference, but blinded quantitative imaging and objective outcomes (survival) strengthen internal validity. |
| () | Experimental in vivo study in mice (PD-L1 heterogeneity imaging) | SYRCLE tool (animal studies) | Selection bias (no treatment groups; small sample of tumor-bearing mice), performance bias (not reported if outcome assessment was blinded), detection bias (objective FLIM measurement of PD-L1), attrition (complete data), reporting bias (all outcomes reported) | Moderate – Methodology was exploratory with a small sample (7 TNBC, 4 HCC mice). No intervention was tested, but lack of blinding/reporting details warrants caution. No obvious bias in measurement was noted, though the small scale and unclear randomization procedures yield some uncertainty. |
| () | Experimental in vivo study in mice (anti-PD-1 therapy efficacy) | SYRCLE tool (animal studies) | Selection bias (random group allocation to anti-PD-1 vs control), performance bias (likely not blinded to treatment), detection bias (outcome measures: FLIM and tumor response – objective but blinding not stated), attrition (no missing animals), reporting bias (complete outcome reporting) | Low–Moderate – A well-designed preclinical study with randomization to treatment vs control groups and objective imaging outcomes. Some risk remains due to absent mention of blinding and the inherent limitations of an animal model, but overall bias is limited. |
| () | Experimental in vivo study in mice (anti-CTLA-4 therapy) | SYRCLE tool (animal studies) | Selection bias (treatment vs control group allocation not fully described), performance bias (blinding of investigators not reported), detection bias (FLIM metabolic readout and response evaluation, likely objective but unblinded), attrition (complete data from 43 mice), reporting bias (full outcome reporting) | Moderate – This animal study tested FLIM on T-cell metabolism as a predictor of anti-CTLA-4 response. It used a reasonable sample size (43 mice) and validated findings with flow cytometry. While no critical flaws were evident, the lack of explicit blinding and potential uncontrolled differences between experimental groups warrant a moderate risk-of-bias rating. |
Risk of bias assessment.
3 Results
Our results are summarized in Table 2. Among the six articles matching our query, five (–) are published studies and one () is a preprint. Of these, five (–, ) focus on in-depth analyses of new methods for assessing anti-PD1/PD-L1 therapy response to improve patient stratification, while one () explores anti-CTLA-4 immunotherapy by evaluating increased free NADH in tissue samples using FLIM. Three articles investigating PD-1/PD-L1 (–) examine the feasibility and correlation between PD-1/PD-L1 interaction (detected by iFRET in ex vivo samples) and patients’ responses to immunotherapy; while the other two (, ) analyze the concordance of FLIM in detecting PD-L1 expression levels in in vivo mouse samples and compare these findings with the IHC PD-L1 score. It is worth noting that three of the five PD-1/PD-L1 studies (–) were conducted by the same research group, and two (, ) by another, potentially contributing to the apparent focus on this pathway. While our dataset is limited, this distribution may still mirror broader trends in the field, with CTLA-4 representing a less-examined but promising direction for future research.
Table 2
| Reference | Target receptor | Study type | Methods | Sample type and size | Key findings | Limitations | Conclusions |
|---|---|---|---|---|---|---|---|
| () | PD-1/PD-L1 and CTLA-4/CD80 | Retrospective observational biomarker study | FLIM/iFRET for the quantification of PD-1/PD-L1 and CTLA-4/CD80 interaction in FFPE tumor samples (ccRCC, melanoma, NSCLC), validated with cell assays. | 22 patients with ccRCC; 176 patients with melanoma; 60 patients with NSCLC(40 with clinical outcome data). | PD-1/PD-L1 interaction varies, not linked to PD-L1 levels; high interaction correlated to better survival in NSCLC/melanoma; iFRET detects even in PD-L1–negative. | Retrospective design, lack of dynamic post-treatment assessment of interactions, and analysis limited to a single tumor region, which may not capture the full extent of intratumoral heterogeneity. | iFRET predicts outcomes better than PD-L1. High interaction indicates better response to PD-1 blockade. iFRET may improve patient stratification. |
| () | PD-1/PD-L1 | Experimental in vitro study | FLIM/iFRET assay to provide a quantitative readout of PD-1/PD-L1 interactive states between cell membranes. | 80 samples used for CMMA construction (HT144 cell line, human melanoma samples, and rat brain cortex tissue) | PD-1/PD-L1 binding between immune and melanoma membranes was successfully quantified using membrane microarrays combined with TR-FRET. | Proof of concept of CMMAs feasibility as a tool. | iFRET with membrane microarrays detects PD-1/PD-L1 without live cells, validated with pembrolizumab. The assay is reproducible, low-labor, and adaptable for immune monitoring and personalized therapy. |
| () | PD-1/PD-L1 | Retrospective observational biomarker study | Automated, high-throughput FLIM/iFRET assay for the quantification of PD-1/PD-L1 interaction, validating the predictive value for stratification and prognosis with the gold standard. | 188 patients with NSCLC | PD-L1 score is less efficient than PD-1/PD-L1 interaction state, measured through FRET efficiency values, in predicting overall survival and therapy response in patients with NSCLC | Retrospective design, high variability in FRET data, incomplete clinical data, and inability to separate tumor-immune from immune-immune interactions. | Measuring PD-1/PD-L1 interaction may be more useful than PD-L1 score by IHC. Prospective studies are needed for validation. |
| () | PD-L1 | Experimental in vivo imaging in murine models | In vitro and in vivo viability proof of Fluorescence Lifetimes (FLT) as a way to quantify PD-L1 expression in TNBC or HCC. | 30 Eight-week-old C57Bl/6 mice, 23 f with TNBC, 4 m with HCC, 3 f for control | FLIM enables noninvasive, real-time measurement of PD-L1 expression and heterogeneity in tumors, offering a dynamic tool to monitor immunotherapy response beyond traditional biopsies. | Only applicable to superficial tissue due to FLT field depth capabilities. | FLT is a viable detection method for PD-L1 expression. |
| () | CTLA-4 | Experimental in vivo imaging in murine models | TD-FLIM of NAD(P)H autofluorescence in lymph node T cells for the evaluation of therapy effectiveness, validated through flow cytometry. | 43 (C57Bl/6 FoxP3-EGFP) mice with B16F0 melanoma. | FLIM detects T-cell metabolic shift with more free NADH linked to better anti-CTLA-4 response. Responders show higher IFN-gamma and activation markers. | Animal model; clinical applicability to humans requires further investigation. | FLIM of NAD(P)H autofluorescence in lymph node T cells is a potential biomarker for early assessment of anti-CTLA-4 immunotherapy effectiveness. |
| () | PD-L1 | Experimental in vivo imaging in murine models | TD-FLIM for the detection of intra-tumor PD-L1 heterogeneity using radiolabeled αPDL1–800 antibodies. | 7 mice with triple-negative breast cancer (TNBC) tumors; 4 mice with hepatocellular carcinoma (HCC) tumors | TD-FLIM was able to quantify intra-tumoral heterogeneity of PD-L1, distinguishing between tumor specific and non-specific signals | Needs further studies with larger sample sizes to support clinical translation to humans | TD imaging provides a quantitative measure of PD-L1 expression, useful for assessing tumor heterogeneity and monitoring response to immunotherapy. |
Data collected from reference papers regarding FLIM and ICI.
Due to substantial heterogeneity across the included studies, particularly in terms of sample type (human tissue, cell lines, and animal models), cancer subtype, and sample size, a quantitative synthesis was not feasible. Instead, a narrative synthesis was conducted to summarize and contextualize the findings.
Sánchez-Magraner et al. (2020) () investigated the limitations of the IHC-measured PD-L1 score (currently the gold standard) in predicting immunotherapy response in cancer patients and proposed an alternative approach based on measuring functional PD-1/PD-L1 interactions through iFRET for improved prognostic and predictive value. The study analyzed patients with non-small cell lung cancer (NSCLC), malignant melanoma, and clear cell renal cell carcinoma (ccRCC). Using FLIM combined with amplified signal detection, the authors measured FRET efficiency between PD-1 and PD-L1 molecules across patient samples. These interaction scores were then correlated with PD-L1 scores and with patient survival outcomes. The study included a retrospective cohort of anti-PD-1-treated metastatic NSCLC patients. The results revealed that not only does FRET efficiency vary significantly both between and within tumors, it also has no correlation with PD-L1 score. Notably, patients with higher PD-1/PD-L1 interaction levels exhibited better responses to immunotherapy and improved survival in melanoma and NSCLC cohorts. This suggests that tumors heavily reliant on PD-1-mediated immune evasion are more vulnerable to PD-1/PD-L1 blockade, a finding that undermines the utility of PD-L1 expression as a predictive biomarker. While the study provided compelling evidence that iFRET can capture clinically relevant checkpoint activity, certain limitations remained underexplored. For instance, the study focused on ranking patients based on iFRET efficiency and correlating it with survival time. While it was found to be statistically significant, it doesn’t discriminate between subgroups, both between tumor stages and the undergone treatment. Furthermore, they performed a single-time-point analysis, which inherently ignores dynamic changes that may occur with treatment.
Sánchez-Magraner et al. (2021) () developed an assay consisting of cell membrane microarrays (CMMAs) derived from HT144 cell lines and melanoma samples to assess PD-1/PD-L1 interactions quantitatively. The study involved incubating the CMMAs with cell membranes isolated from peripheral blood mononuclear cells, which expressed PD-1. The PD-1/PD-L1 interaction was then quantified through time-resolved FRET. To validate the specificity of this interaction, they performed the assays both in the presence and absence of Pembrolizumab, an anti-PD-1 ICI. The results showed the assay’s capability to effectively quantify PD-1/PD-L1 interactions. Notably, the interaction was disrupted when pembrolizumab was present, confirming also the assay’s sensitivity to targeted inhibition of PD-1/PD-L1 binding. However, this study represents only a proof of concept of the feasibility of CMMAs as a tool.
Sánchez-Magraner et al. in 2023 () expanded on the findings of the 2020 study (). Their research explored whether quantifying PD-1/PD-L1 interactions in Formalin-Fixed Paraffin-Embedded tissue samples, taken from a cohort of 188 patients with in-situ or metastatic NSCLC treated with immune checkpoint inhibitors, could support effective patient stratification and identify candidates for immune checkpoint blockade therapy. This analysis was conducted using a high-throughput, automated, quantitative imaging platform called “QF-Pro”, based on iFRET. The results revealed no correlation between PD-1/PD-L1 interaction and PD-L1 score. The PD-L1 score was found to have a very weak correlation with patient prognosis. Contrarily, PD-1/PD-L1 interaction was shown to have a strong positive correlation (p<0.0001) with the anti-PD-1/PD-L1 therapy response (patients exhibiting high FRET efficiency demonstrated improved survival outcomes). While the study highlights the potential of QF-Pro to quantify PD-1/PD-L1 complex formation and aid in patient stratification, it also presents several limitations. Firstly, the method introduces considerable intra- and inter-patient variability, requiring careful sampling to ensure consistency. The retrospective design limits the ability to confirm predictive value, emphasizing the need for prospective validation. The lack of detailed clinical data, such as smoking status, and the inability to distinguish between tumor-immune and immune-immune interactions, further constrain the findings.
Pal et al. (2023) () investigated the use of time-domain (TD) fluorescence imaging to measure the expression of PD-L1 in tumors. Researchers employed a PD-L1-specific antibody labeled with IRDye 800CW (αPDL1-800) to perform in vivo TD fluorescence imaging in murine models. They conducted both wide-field imaging for superficial triple-negative breast cancer (TNBC) tumors and tomographic imaging for deeper-seated hepatocellular carcinoma (HCC) tumors. The fluorescence lifetime (FLT) of αPDL1–800 served as a quantitative measure of PD-L1 expression. The study demonstrated that FLT measurements could effectively differentiate between specific and nonspecific accumulation of αPDL1-800, allowing for accurate quantification of PD-L1 expression. In TNBC models, FLT imaging revealed significant inter-tumoral heterogeneity in PD-L1 levels. Furthermore, in vivo FLT findings correlated well with ex vivo assessments, including western blot and immunohistochemistry. In HCC models, TD tomographic imaging successfully quantified PD-L1 expression in tumors located more than 5 mm beneath the surface, highlighting the technique’s capability to assess deep-seated tumors. The research suggests that TD fluorescence imaging offers a robust, non-invasive method for quantifying PD-L1 expression in both superficial and deep tumors. This approach could enhance the assessment of tumor heterogeneity and improve monitoring of responses to immunotherapy, thereby aiding in the selection of appropriate patients for such treatments. The main drawback of this study is the small sample size. Further studies are needed to assess clinical feasibility on humans.
Pal et al. (2025) () proved the applicability of time-domain FLIM for noninvasive, quantitative in vivo assessment of PD-L1 expression and intertumoral heterogeneity in intact tumor models. Recognizing the limitations of IHC, the authors addressed the inadequacy of ex vivo, static, and regionally limited measurements in capturing the dynamic and heterogeneous nature of PD-L1 within and across tumors. The researchers conjugated a monoclonal anti-PD-L1 antibody (clone 29E.2A3) to the near-infrared fluorophore αPDL1–800 and validated its PD-L1 specificity using both in vitro and in vivo models. In vitro, FLT increased upon binding of αPDL1–800 to PD-L1, distinguishing it from nonspecifically accumulated probes. This FLT shift correlated linearly with PD-L1 expression levels modulated by IFNγ treatment in E0771 and RIL-175 cell lines. Both FLIM microscopy and Western blot analysis (r² = 0.89) were used to strengthen the results. For in vivo validation, wide-field TD-FLT imaging was conducted on murine models of triple-negative breast cancer (TNBC, E0771) and hepatocellular carcinoma (RIL-175). The tumor-associated FLT of PD-L1-bound αPDL1–800 was consistently longer than that of unbound probes in normal tissue, enabling the separation of specific from nonspecific signals. This separation facilitated the calculation of normalized amplitude ratios, which exhibited a robust correlation with PD-L1 expression measured by Western blot (r² = 0.96), outperforming fluorescence intensity alone. The technique was further applied to monitor immunotherapy-induced PD-L1 upregulation in anti-PD-1 treated TNBC mice, where both FLT and aT/aNS ratios detected significant increases in PD-L1 expression relative to controls (p<0.01). Importantly, the study demonstrated FLT imaging capacity for quantifying baseline heterogeneity and treatment-induced modulation of PD-L1 in superficial and deep-seated tumors via planar and tomographic imaging. While this study demonstrated the applicability in vivo on mice, translation into human practice is hindered by the field depth of FLT, which doesn’t allow for measuring expression in non-superficial tissues.
Isozimova et al. (2023) () aimed to validate the use of NAD(P)H autofluorescence lifetime of T cells within lymph nodes as a predictive biomarker for response to anti-CTLA-4 immunotherapy. The research focused on assessing metabolic changes in immune cells as indicators of treatment efficacy. The study utilized C57Bl/6 FoxP3-EGFP transgenic mice with B16F0 melanoma implanted near the inguinal lymph node. Mice were treated with anti-CTLA-4 antibodies. Lymph nodes were harvested 1–2 days post-treatment and analyzed with a FLIM-equipped microscope. Decay curves were fitted into a model to determine NAD(P)H lifetime components. Flow cytometry assessed activation markers (CD25, CD69) and cytokine production (IFN-γ) in CD4+ and CD8+ T cells. Anti-CTLA-4 treatment led to a trend towards reduced tumor growth compared to controls, with significant differences observed on day 11. However, variability in tumor response was noted, with some mice showing pronounced growth inhibition and others minimal response. FLIM data revealed that responder mice exhibited a higher proportion of the free NADH form associated with glycolysis than non-responders. This shift suggests enhanced metabolic activity in activated T cells. The average NAD(P)H lifetime did not differ significantly between groups. Responder mice showed increased expression of activation markers CD25 and CD69, and higher IFN-γ production in both CD4+ and CD8+ T cells, indicating effective immune activation. Non-responders did not exhibit these changes, aligning with FLIM findings. One key limitation of this study is that it did not explore the long-term effects of immunotherapy or the correlation between early metabolic changes and long-term treatment outcomes. Furthermore, the cohort of mice was limited in size, requiring further studies for human applicability.
4 Discussion
4.1 IHC as the gold standard
Currently, the standardized FDA-approved method in almost all Pathology Departments all over the globe to quantify IC expression (i.e., PD-L1) is immunohistochemistry, through approved kits with specific antibodies (i.e., 28-8, 22C3, SP263, and SP142) (). Based on immunohistochemical analysis, compared to non-expressing subjects, patients with immune checkpoint overexpression present with a stronger antitumor activity and are more likely to benefit from ICI (, , ). However, although it is an “easy-to-use”, fast, and inexpensive method, as for other immunohistochemical evaluations, it can only provide a momentary picture of the microenvironmental status in a confined region of ex vivo specimen; furthermore, protein expression could be influenced by the concentration of fixative used or other variables related to instruments used, or the inter-observer variability on data interpretation (, ).
4.2 FLIM
FLIM has evolved exponentially from 1988, when it was first introduced, until today; merging theoretical techniques with biomedical research. Nowadays, it can be used in combination with other imaging technologies to gather further information about the cellular microenvironment.
Recently, FLIM has gained technological advancements resulting in an improvement in the precision of analysis, as well as a broadening of this technology’s applications. These advancements have allowed it to match the precision of IHC for the analysis of ICI therapy at a microenvironmental level (–). However, it is unclear how responders can be differentiated from non-responders. Traditionally, IHC has been used to quantify the expression of receptors, but the expression alone does not greatly correlate to efficacy. On the contrary, functional engagement measured with FLIM between drug and receptor is a promising predictor for the success of the therapy by measuring it independently from their concentration. The clinical application would mean the inclusion of low-expressing patients who would normally be excluded from the therapy or the exclusion of non-responding high-presenting patients who would needlessly suffer the side effects.
4.3 FLIM’s advantages & limitations
FLIM and FRET are reliable imaging techniques that could overcome some of the limitations of IHC. Table 3 shows a direct comparison between the technical and practical capabilities of IHC and FLIM. While IHC is the gold standard for predicting the body’s response to various ICIs, its limitations have become increasingly evident (). Despite the scarce research on this topic, the usage of FLIM and FRET to test ICI efficacy have shown promising results by providing real-time, non-invasive insights into molecular interactions such as PD-1/PD-L1 engagement, surpassing the static and limited biopsy samples used in IHC. FLIM detected treatment-induced changes in tumors in vivo just 2 days post-treatment, which is earlier than detectable changes in tumor volume (). Furthermore, FLIM-FRET allows for the visualization of checkpoint interactions at a microscopic level, providing crucial information about the functional state of these molecules as shown by iFRET which detected significant interaction states in patients who were PD-L1 negative according to IHC (). FLIM can help detect cells’ in vivo metabolism with no phototoxicity and in real-time. FLIM’s capability to quantify functional interactions offers a more comprehensive approach, potentially improving the stratification of patients for immunotherapy and reducing the ambiguity associated with IHC-based assays. It is important to underline that FLIM finds its greatest potential in vivo and relies on the fact that its results, unlike traditional fluorescence microscopies, are not dependent on the change in fluorescence intensity but on the lifetime. FLIM, with or without FRET, still suffers from major drawbacks that vary depending on its specific application. The use of FLIM technology in the analysis of ex vivo samples proves it is non-superior to more widespread methods since metabolic microenvironment characteristics are lost in the transition from the in vivo to the ex vivo, limiting its ability to provide accurate insights into molecular interactions.
Table 3
| FLIM | IHC | References | |
|---|---|---|---|
| Principle | Fluorescence lifetime measurement | Detection of antigen–antibody binding | (, –) |
| Contrast Mechanism | Differences in fluorescence lifetime | Chromogenic/fluorescent signal | (, –) |
| Multiplexing | High (lifetime-based separation) | Moderate (spectral separation) | (, –) |
| Functional Data | Yes (biochemical and metabolic information) | Limited (depends on the marker) | (, , , ) |
| Sample Type | Live or fixed samples; 2D or 3D | Fixed or fresh samples; 2D | (–, –) |
| Clinical Use | Research and emerging clinical applications | Routine clinical pathology | (, , ) |
| Time | Depending on the complexity, estimation model, and multiplexing, up to multiple days. | Hours up to a day | (, , , , ) |
| Training required | A good understanding of fluorescence theory, FLIM system principles, and experimental procedures is required due to the highly specialized equipment | Standard technician or pathologist training, with high degrees of automation | (, , , ) |
| Cost | High, due to advanced technological equipment. Some setups (e.g., frequency-domain FLIM) are relatively less expensive | Low, as the reagents constitute the main cost | (, , , , , ) |
| Time to detect changes after treatment | As early as 2 days post-treatment (via metabolic contrast) | At least 6 days post-treatment (via changes in tumor volume) | () |
Comparison between FLIM and IHC.
Hence, the true power of FLIM resides in its in vivo application. One viable way to adopt FLIM in an ex vivo context would be through FLIM used with Raman spectroscopy () as the tissue cryosections partially maintain the in vivo microenvironment. However, FLIM-FRET detection probes are unsuitable when using this technique due to the need for a non-frozen tissue for their employment rendering this technique limited. The probes are a major issue even in the in vivo applications of FLIM-FRET since they are scarce in number and the existing ones yet unsuitable for human patients.
FLIM also presents some minor challenges that further research can work to resolve. For example, since the lifetime duration computation is based on statistics, the higher the number of iterations, the higher the precision and certainty of measurements. This implies that a drastic increase in time is required to obtain robust values, especially in multiplexing applications (). Notably, scalability for clinical use is being addressed by innovations such as GPU-accelerated high-speed FLIM, which significantly reduces imaging and processing times (). Deep learning approaches, such as Phasor U-Net, automate and accelerate lifetime extraction and multiplexing, minimizing manual intervention and enabling rapid, accurate analysis even with limited photon counts (). High-throughput acquisition systems using array detectors and parallelized photon counting further increase scalability ().
Another problem of FLIM in vivo applicability is the depth of measurements (). Until 2024, the number of tumors analyzed in vivo with this technique is minimal (mainly melanomas due to their easily accessible location). Tissue depth penetration is limited as with all optical imaging modalities, and with two-photon FLIM it is around 100-130 μm (), in vivo visualization of deep tissues (i.e., intestine, kidneys, liver) is currently limited to invasive approaches.
Since FLIM-FRET works with standard confocal microscopy, the maximum resolution possible is 200–250 nanometers (), which is enough to make it a valuable option in studying molecular interactions and changes in the microenvironment. However, it is not comparable to other microscopy techniques (i.e., electron microscopy) although they have other serious drawbacks such as phototoxicity.
An additional challenge associated with FLIM-FRET is the complexity and the technical expertise required for its implementation. It requires strict protocols to reduce interference from extrinsic factors (i.e., pH, temperature, etc.) that may affect fluorescence decay times () and a profound knowledge of the biological environments and pathways involved.
Despite these barriers, commercial development is underway, companies such as JenLab (–) are offering FLIM-based devices for dermatological applications, indicating momentum towards clinical implementation.
Also, the cost and resource intensity of FLIM-FRET systems pose a significant barrier; the advanced imaging equipment required is expensive and often requires specialized maintenance. The economic constraint can hinder the broader adoption of FLIM-FRET in clinical practice, despite its potential benefits.
4.4 Future perspectives
The utilization of FLIM and FLIM/FRET is expected to have a great impact on future clinical practice (, ) considering the effect on cancer patients’ diagnosis given the high specificity and sensitivity of the technique, particularly regarding genetically encoded biosensors reviewed by Vu et al. (). In 2023 it has been shown that high precision and accuracy (respectively closeness of known values among them and closeness of known values with the true one) guarantee a delved and highly specific landscape of the cellular metabolism and molecular interactions previously presented in the ICI section.
This novel technology encompasses the current trend of personalized precision medicine. We are gradually diving into having a treatment specific to each patient for high-quality care and patient management.
The current state-of-art of FLIM technology strongly suggests that intraoperative guidance use of FLIM has been emerging as a relevant and consistent future application of the mentioned technology. In this setting, FLIM is invasive, as it requires direct access to tissue during surgical procedures, but it enables real-time imaging capabilities (). At the same time, non-invasive applications are also advancing, particularly in dermatology (–). These highlight that there is still an optimal margin to further enhance this microscopy in both domains.
Practical pipeline development for broader clinical integration of FLIM involves creating comprehensive training programs for laboratory technologists and pathologists, deploying automated, ready-to-use FLIM systems with standardized protocols, and embedding FLIM modules into existing histopathology and cytometry platforms. Open-source toolkits like FLIMJ facilitate integration with established image analysis workflows, reducing the barrier for adoption in clinical laboratories (). Regulatory pathway development and multi-institutional validation studies are essential for clinical acceptance.
Overall, the topic remains mostly underexplored, and further research is needed to better understand the potential of known and alternative immune checkpoint pathways such as CTLA-4, TIM-3, and LAG-3.
5 Limitations
Although our article is based on robust guidelines for drafting, it does have some limitations. The exclusion of articles written in languages other than English and Italian may have limited the scope of our literature search. Restricting our search to only PubMed, Scopus, and Embase may have excluded relevant studies available in other databases, journals, or websites. Additionally, the keywords and MeSH employed for the research may have excluded other relevant studies.
6 Conclusions
The quantification of the Immune Checkpoint Inhibitor response remains a critical challenge in cancer therapy. Traditional techniques like immunohistochemistry do not have high accuracy and commonly fail to meet the desired reliability in predicting response. FLIM and FRET offer a promising alternative by enabling real-time visualization and quantifying molecular interactions within the tumor microenvironment.
Other novel imaging techniques, integrating emerging platforms like CyTOF, multiplexed immunofluorescence, and spatial proteomics, should be further investigated to unlock new avenues for biomarker discovery and therapeutic stratification.
Future research should focus on refining FLIM and FRET methodologies to quantify the effects of Immune Checkpoint Inhibitors, linking them to patient outcomes. This could be explored through the use of current biomarkers, novel biomarkers, and innovative FLIM and FRET protocols. By combining these advanced approaches, there is the potential to make a breakthrough in the cancer immunotherapy landscape, aiming at a more personalized treatment for patients.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.
Author contributions
CC: Writing – original draft, Writing – review & editing. GF: Writing – original draft, Writing – review & editing. ML: Writing – original draft, Writing – review & editing. GM: Writing – original draft, Writing – review & editing. AM: Writing – original draft, Writing – review & editing. FP: Writing – original draft, Writing – review & editing. RW: Writing – review & editing. AD: Supervision, Writing – review & editing. PC: Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. The publication fee for this work was covered by the Italian Ministry of Health’s ‘Ricerca Corrente’ funding to IRCCS Humanitas Research Hospital.
Acknowledgments
We acknowledge the use of OpenAI’s ChatGPT to assist in drafting the initial skeleton of this manuscript. All content has been written, thoroughly reviewed, and verified by the authors.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1626608/full#supplementary-material.
Abbreviations
αPDL1-800, Antibody against PD-L1 labeled with 800 nm fluorophore; ccRCC, clear cell renal cell carcinoma; CMMAs, Cell Membrane Microarrays; CTLA-4, Cytotoxic T-Lymphocyte-Associated Protein 4; EGFP, Enhanced Green Fluorescent Protein; FAD, Flavin Adenine Dinucleotide; FLIM, Fluorescence Lifetime Imaging Microscopy; FLT, Fluorescence Lifetime; FoxP3, Forkhead Box P3; FRET, Förster Resonance Energy Transfer; HCC, hepatocellular carcinoma; ICI, Immune Checkpoint Inhibitor; IFN-γ, Interferon Gamma; iFRET, Immune Förster Resonance Energy Transfer; IHC, Immunohistochemistry; IL-2, Interleukin-2; IRDye 800CW, A near-infrared (NIR) fluorescent dye; LAG-3, Lymphocyte Activation Gene-3; NAD(P)H, Nicotinamide Adenine Dinucleotide (Phosphate); NADH, Nicotinamide Adenine Dinucleotide; NSCLC, non-small cell lung cancer; PD-1, Programmed Death receptor-1; PD-L1, Programmed Death-Ligand 1; SHP-2, Src Homology region 2 domain-containing Phosphatase-2; TCR, T Cell Receptor; TCSPC, Time-Correlated Single Photon Counting; TD, Time Domain; TD-FLIM, Time Domain Fluorescence Lifetime Imaging Microscopy; TIM-3, T-cell Immunoglobulin and Mucin-domain containing-3; TNBC, triple-negative breast cancer; TPS, Tumour Proportion Score; Treg, Regulatory T Cell.
References
1
SharmaPHu-LieskovanSWargoJARibasA. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. (2017) 168:707–23. doi: 10.1016/j.cell.2017.01.017
2
CatalanoMIannoneLFNesiGNobiliSMiniERovielloG. Immunotherapy-related biomarkers: Confirmations and uncertainties. Crit Rev Oncol Hematol. (2023) 192:104135. doi: 10.1016/j.critrevonc.2023.104135
3
BeckerW. Fluorescence lifetime imaging – techniques and applications. J Microscopy. (2012) 247:119–36. doi: 10.1111/j.1365-2818.2012.03618.x
4
TCSPC | What is Time-Correlated Single Photon Counting? 2 Bain Square, Kirkton Campus, Livingston, EH54 7DQ: Edinburgh Instruments (2023). Available online at: https://www.edinst.com/blog/what-is-tcspc/ (Accessed April 15, 2025).
5
LiaoSSunYCoskunUC. FLIM Analysis using the Phasor Plots. Champaign, Illinois (USA): ISS, Inc. (2015).
6
MoroneDAutiliaFDSchornTErreniMDoniA. Evaluation of cell metabolic adaptation in wound and tumour by Fluorescence Lifetime Imaging Microscopy. Sci Rep. (2020) 10:6289. doi: 10.1038/s41598-020-63203-4
7
Pietraszewska-BogielAGadellaTWJ. FRET microscopy: from principle to routine technology in cell biology. J Microscopy. (2010) 241:111–8. doi: 10.1111/j.1365-2818.2010.03437.x
8
Sánchez-MagranerLMilesJBakerCLApplebeeCJLeeDJElsheikhSet al. High PD-1/PD-L1 checkpoint interaction infers tumor selection and therapeutic sensitivity to anti-PD-1/PD-L1 treatment. Cancer Res. (2020) 80:4244–57. doi: 10.1158/0008-5472.CAN-20-1117
9
Sánchez-MagranerLde la FuenteMEvansCMilesJElexpeARodriguez-AstigarragaMet al. Quantification of PD-1/PD-L1 interaction between membranes from PBMCs and melanoma samples using cell membrane microarray and time-resolved förster resonance energy transfer. Analytica. (2021) 2:156–70. doi: 10.3390/analytica2040015
10
Sánchez-MagranerLGumuzioJMilesJQuimiNDel Prado MartínezPAbad-VillarMTet al. Functional engagement of the PD-1/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non-small-cell lung cancer. J Clin Oncol. (2023) 41:2561–70. doi: 10.1200/JCO.22.01748
11
PalRKrishnamoorthyMMatsuiAKangHMoritaSTaniguchiHet al. Fluorescence lifetime imaging enables in vivo quantification of PD-L1 expression and intertumoral heterogeneity. Cancer Res. (2025) 85:618–32. doi: 10.1158/0008-5472.CAN-24-0880
12
IzosimovaAVMozherovAMShirmanovaMVShcheslavskiyVISachkovaDAZagaynovaEVet al. Fluorescence lifetime imaging of NAD(P)H T cells autofluorescence in the lymphatic nodes to assess the effectiveness of anti-CTLA-4 immunotherapy. Sovrem Tekhnologii Med. (2023) 15:5–15. doi: 10.17691/stm2023.15.3.01
13
KumarAPalRKrishnamoorthyMMatsuiAKangHMoritaSet al. In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging. Res Square (Research Square). (2023). doi: 10.21203/rs.3.rs-3222037/v1. Preprint.
14
PrinceEASanzariJKPandyaDHuronDEdwardsR. Analytical Concordance of PD-L1 assays utilizing antibodies from FDA-Approved diagnostics in advanced Cancers: a Systematic literature review. JCO Precis Oncol. (2021) 5):953–73. doi: 10.1200/po.20.00412
15
MariamAKamathSSchvederKMcLeodHLRotroffDM. Biomarkers for response to Anti–PD-1/Anti–PD-L1 immune checkpoint inhibitors: A Large Meta-Analysis. Oncology. (2023) 3705):210–9. doi: 10.46883/2023.25920995
16
DavisAAPatelVG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J ImmunoTher Cancer. (2019) 7:278. doi: 10.1186/s40425-019-0768-9
17
IlieMHofmanVDietelMSoriaJCHofmanP. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Archiv. (2016) 468:511–25. doi: 10.1007/s00428-016-1910-4
18
SanguedolceFZanelliM. “Assessing PD-L1 expression in different tumor types.” In: Handbook of Cancer and Immunology. RezaeiN. (ed). Switzerland: Springer, Cham (2022) pp. 1–21. doi: 10.1007/978-3-030-80962-1_168-1
19
ChenLCLloydWRChangCWSudDMycekMA. Fluorescence lifetime imaging microscopy for quantitative biological imaging. Methods Cell Biol. (2013) 114:457–88. doi: 10.1016/B978-0-12-407761-4.00020-8
20
BastiaensPISquireA. Fluorescence lifetime imaging microscopy: spatial resolution of biochemical processes in the cell. Trends Cell Biol. (1999) 9:48–52. doi: 10.1016/s0962-8924(98)01410-x
21
van MunsterEBGadellaTW. Fluorescence lifetime imaging microscopy (FLIM). Adv Biochem Engineering/Biotechnol. (2005) 95:143–75. doi: 10.1007/b102213
22
HussainiHMSeoBRichAM. Immunohistochemistry and immunofluorescence. Methods Mol Biol (Clifton N.J.). (2023) 2588:439–50. doi: 10.1007/978-1-0716-2780-8_26
23
MagakiSHojatSAWeiBSoAYongWH. An introduction to the performance of immunohistochemistry. Methods Mol Biol (Clifton N.J.). (2019) 1897:289–98. doi: 10.1007/978-1-4939-8935-5_25
24
LiAYangDH. Application of immunohistochemistry in basic and clinical studies. Methods Mol Biol (Clifton N.J.). (2020) 2108:43–55. doi: 10.1007/978-1-0716-0247-8_4
25
HwangWMcPartlandTJeongSEvansCL. A robust method for autofluorescence-free immunofluorescence using high-speed fluorescence lifetime imaging microscopy. Sci Rep. (2025) 15:5503. doi: 10.1038/s41598-025-89142-6
26
ThieleJCHelmerichDAOleksiievetsNTsukanovRButkevichESauerMet al. Confocal fluorescence-lifetime single-molecule localization microscopy. ACS Nano. (2020) 14:14190–200. doi: 10.1021/acsnano.0c07322
27
ChenTHongRMagdaDBieniarzCMorrisonLMillerLWet al. Time gated luminescence imaging of immunolabeled human tissues. Analytical Chem. (2017) 89:12713–9. doi: 10.1021/acs.analchem.7b02734
28
DmitrievRIIntesXBarrosoMM. Luminescence lifetime imaging of three-dimensional biological objects. J Cell Sci. (2021) 134:1–17. doi: 10.1242/jcs.254763
29
NakabayashiTAwasthiKOhtaN. Application of fluorescence lifetime imaging (FLIM) to measure intracellular environments in a single cell. Adv Exp Med Biol. (2017) 1035:121–33. doi: 10.1007/978-3-319-67358-5_8
30
RaabSS. The cost-effectiveness of immunohistochemistry. Arch Pathol Lab Med. (2000) 124:1185–91. doi: 10.5858/2000-124-11
31
DattaRHeasterTMSharickJTGilletteAASkalaMC. Fluorescence lifetime imaging microscopy: fundamentals and advances in instrumentation, analysis, and applications. J Biomed Optics. (2020) 25:1. doi: 10.1117/1.jbo.25.7.071203
32
BeckerLJanssenNLaylandSLMürdterTENiesATSchenke-LaylandKet al. Raman Imaging and fluorescence lifetime imaging microscopy for diagnosis of cancer state and metabolic monitoring. Cancers. (2021) 13:5682. doi: 10.3390/cancers13225682
33
CLevittJAPolandSPKrstajicNPfistererKErdoganABarberPRet al. Quantitative real-time imaging of intracellular FRET biosensor dynamics using rapid multi-beam confocal FLIM. Sci Rep. (2020) 10:5146. doi: 10.1038/s41598-020-61478-1
34
LiuYLuoGZhaoFGaoJShaoXLiKet al. Multiplexing and sensing with fluorescence lifetime imaging microscopy empowered by phasor U-net. Anal Chem. (2025) 97:11360–9. doi: 10.1021/acs.analchem.5c02028
35
ZhangZLiuXHeMHuangYXuLHanYet al. High-throughput multiplexed fluorescence lifetime microscopy. Opt Lett. (2023) 48:5547–50. doi: 10.1364/OL.503136
36
LinFZhangCZhaoYShenBHuRLiuLet al. In vivo two-photon fluorescence lifetime imaging microendoscopy based on fiber-bundle. Opt Lett. (2022) 47:2137–40. doi: 10.1364/OL.453102
37
GuyCMitreaDMChouPCTemirovJVignaliKMLiuXet al. LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation. Nat Immunol. (2022) 23:757–67. doi: 10.1038/s41590-022-01176-4
38
KönigK. Review: Clinical in vivo multiphoton FLIM tomography. Methods Appl Fluoresc. (2020) 8:034002. doi: 10.1088/2050-6120/ab8808
39
KönigKBreunigHGBatistaASchindeleAZiegerMKaatzM. Translation of two-photon microscopy to the clinic: multimodal multiphoton CARS tomography of in vivo human skin. J BioMed Opt. (2020) 25:1–12. doi: 10.1117/1.JBO.25.1.014515
40
LentschGValdebranMSakniteISmithJLindenKGKönigKet al. Non-invasive optical biopsy by multiphoton microscopy identifies the live morphology of common melanocytic nevi. Pigment Cell Melanoma Res. (2020) 33:869–77. doi: 10.1111/pcmr.12902
41
VuCQAraiS. Quantitative imaging of genetically encoded fluorescence lifetime biosensors. Biosensors. (2023) 13:939. doi: 10.3390/bios13100939
42
WeyersBWMarsdenMSunTBecJBewleyAFGandour-EdwardsRFet al. Fluorescence lifetime imaging for intraoperative cancer delineation in transoral robotic surgery. Trans Biophotonics. (2019) 68:857–68. doi: 10.1002/tbio.201900017
43
GaoDBarberPRChackoJVKader SagarMARuedenCTGrislisARet al. FLIMJ: An open-source ImageJ toolkit for fluorescence lifetime image data analysis. PloS One. (2020) 15:e0238327. doi: 10.1371/journal.pone.0238327
Summary
Keywords
FLIM, ICI, IFRET, PD1, PDL1, CTLA4, immunotherapy
Citation
Cossa C, Frigato G, Lupo M, Mazzeo G, Moro A, Patrucco F, Wang R, Doni A and Colombo P (2025) Predicting immune checkpoint inhibitors response via fluorescence lifetime imaging microscopy: a systematic review. Front. Immunol. 16:1626608. doi: 10.3389/fimmu.2025.1626608
Received
11 May 2025
Accepted
16 September 2025
Published
06 October 2025
Volume
16 - 2025
Edited by
Jesus Pacheco-Torres, Johns Hopkins University, United States
Reviewed by
Joyeeta Talukdar, All India Institute of Medical Sciences, India
Alessia Volpe, Memorial Sloan Kettering Cancer Center, United States
Updates
Copyright
© 2025 Cossa, Frigato, Lupo, Mazzeo, Moro, Patrucco, Wang, Doni and Colombo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Massimo Lupo, massimo.lupo@st.hunimed.eu
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.